Avicenna Biosciences, Inc.

Avicenna Biosciences is a Durham, North Carolina-based drug development company leveraging machine learning and medicinal chemistry to revolutionize the lead optimization process. We accelerate the discovery of life-saving drugs by applying artificial intelligence to identify and refine promising drug candidates. Our platform dramatically reduces the time and cost associated with drug development, transforming sub-optimal candidates into viable treatments. We specialize in the development of orally available, CNS-penetrant ROCK inhibitors, with recent successes including initiating IND-enabling studies just one year after program launch.

At Avicenna Biosciences, we focus on solving the critical bottlenecks that often halt drug development. Our ML-driven platform streamlines the entire lead optimization workflow, from initial design to preclinical studies.

We are dedicated to improving patient outcomes through innovative drug development solutions. Our team combines deep expertise in chemistry, biology, and data science to deliver exceptional results for our partners. We are committed to advancing the field of biotechnology and bringing new therapies to market faster.